Real-World Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative Colitis

Filgotinib is a small molecule with preferential inhibition of Janus kinase type 1, approved for the treatment of ulcerative colitis in Scotland in May 2022. We present the first real world experience on its use in clinical practice. In this retrospective, observational, cohort study we assessed pat...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Crohn's and colitis 2023-12
Main Authors: Gros, Beatriz, Goodall, Mairi, Plevris, Nik, Constantine-Cooke, Nathan, Elford, Alexander T, O'Hare, Claire, Noble, Colin, Jones, Gareth-Rhys, Arnott, Ian D, Lees, Charlie W
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Filgotinib is a small molecule with preferential inhibition of Janus kinase type 1, approved for the treatment of ulcerative colitis in Scotland in May 2022. We present the first real world experience on its use in clinical practice. In this retrospective, observational, cohort study we assessed patients with active ulcerative colitis who received filgotinib in NHS Lothian, Scotland. Baseline demographic, phenotype and follow-up data were collected via review of electronic medical records. We included 91 patients with median treatment duration of 39 weeks (IQR 23-49). Among the cohort, 67% (61/91) were biologic and small molecule naïve, whilst 20.9% (19/91) had failed one and 12.1% (11/91) ≥2 classes of advanced therapy. Of the biologic and small molecule naïve patients, 18% (11/61) were also thiopurine naïve. Clinical remission (partial Mayo score
ISSN:1873-9946
1876-4479
DOI:10.1093/ecco-jcc/jjad187